Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Kotak Mahindra Bank Limited - Shareholders meeting

10h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KMBKY KOTAKBANK 500247

0
Canada's biggest public pension fund to step up investment in India

16h reuters
MUMBAI, July 19 (Reuters) - Canada’s biggest public pension scheme sees India as its main focus for investment in Asia as the country pours money into infrastructure development.
500825 PHOENIXLTD KMBKY BRTQY KOTAKBANK 500696 HINDUNILVR 500247 BRITANNIA 503100

0
Kotak Bank slumps to 9-month low

17h thehindubusinessline
Shares of Kotak Mahindra Bank fell the most in nearly 9 months on profit miss. The stock plunged as much as 4.6 per cent to Rs 1,333.85, its lowest in more than two weeks. The stock posted biggest percentage loss since October 25, 2017.
KMBKY KOTAKBANK TRI 500247

0
Kotak Mahindra Bank shares slips 2% after provisions more than doubled in Q1

19h moneycontrol
Kotak Mahindra Bank share price declined 2 percent after its provisions for bad loans shot up 130 percent to Rs 469.6 crore for the quarter ended June compared to previous year. The sequential increase in provisions 53 percent percent.
KMBKY KOTAKBANK 500247

0
Kotak Mahindra Bank reports 12% rise in profit, but misses estimates

20h livemint
Mumbai: Kotak Mahindra Bank Ltd on Thursday said its net profit for the June quarter rose 12.3% from a year ago helped by higher net interest income and other income. Standalone net profit for the first quarter stood at Rs 1,024.94 crore against Rs 912.73 crore a year ago. According to 10 Bloomberg analysts’ estimate, the bank was expected to post a profit of Rs 1,208.50 crore.
KMBKY KOTAKBANK 500247

0
Kotak Mahindra Bank Q1 net profit up 12.3% at Rs 1,025 cr, provisions up 130%

20h moneycontrol
Private sector lender Kotak Mahindra Bank posted a 12.3 percent rise in its first quarter net profit missing estimates, on the back of a 130.5 percent increase in provisions. The bank posted a net profit of Rs 1,024.94 crore in Q1 compared to Rs 912.73 crore YoY.
KMBKY KOTAKBANK 500247

0
Kotak Mahindra Bank Limited - Financial Result Updates

20h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KMBKY KOTAKBANK 500247

0
Kotak Bank, Bajaj Finserv, ABB results

2018-07-18 thehindubusinessline
Thursday will see a host of most actively tracked companies declaring their results for the period ended June 2018. Among these are 21st Century, AB Money, ABB, Bajaj Finserv, Bajaj Finance, Bharat Immunologicals, DB Corp, GNA Axles, Hatsun Agro, Integra Engineering, Kotak Mahindra Bank, Omax Autos, RBL Bank, Shree Digvijay Cement, Sterlite Technologies, Sagar Cements, South India Paper, Suraj, VLS Finance, Valecha Engineering and Vikas EcoTech.
VALECHAENG SAGCEM OMAXAUTO KMBKY SHREDIGCEM 532978 502090 STRTECH 511333 530961 VIKASECO 532389 SRLRY BAJAJFINSV 502180 BAJFINANCE 532374 KOTAKBANK BJJQY 520021 500247 VLSFINANCE 500034

0
Kotak Mahindra Bank Limited - Updates

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KMBKY KOTAKBANK 500247

1
Market capitalisation of nine of top 10 most valued cos zoom Rs 1.58 lakh cr

2018-07-15 moneycontrol
Combined market capitalisation of nine of the 10 most valued companies surged by a whopping Rs 1,58,882.34 crore last week, helped by an overall strong broader market and smart surge in the valuation of Reliance Industries Ltd (RIL).
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

1
M-cap of nine of top 10 most valued firms zoom Rs 1.58 lakh cr

2018-07-15 thehindubusinessline
Over the last week, the Sensex recorded a significant rise of 883.77 points. File Photo - BusinessLine
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...